Placebo News and Research

RSS

Calcium plus vitamin D may help prevent weight gain in postmenopausal women

Postmenopausal women who take calcium and vitamin D supplements may gain less weight than those who do not, although the overall effect is small, according to a report in the May 14 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

15 May 2007

Omega-3 fatty acids may lower risk of Alzheimer's

Nutritionists have long endorsed fish as part of a heart-healthy diet, and now some studies suggest that omega-3 fatty acids found in the oil of certain fish may also benefit the brain by lowering the risk of Alzheimer's disease.

10 May 2007

FDA approves skin patch designed to treat symptoms of early Parkinson's disease

Rotigotine is a drug not previously approved in the United States. Neupro is the first transdermal patch approved for the treatment of symptoms of Parkinson's disease.

10 May 2007

Rosuvastatin well tolerated by a broad range of patients with dyslipidemia

The safety and tolerability of rosuvastatin were assessed using data from 16,876 patients who received rosuvastatin 5-40 mg in a multinational phase II/III/IIIb/IV program, representing 25,670 patient-years of continuous exposure to rosuvastatin. An integrated database, consisting of 33 trials whose databases were locked up to and including September 16, 2005, was used to examine adverse events and laboratory data.

9 May 2007

FluMist may help reduce the burden of seasonal influenza

MedImmune, Inc. has announced research results showing that use of FluMist(R) (Influenza Virus Vaccine Live, Intranasal) in daycare and school settings may help reduce the burden of seasonal influenza.

9 May 2007

Abbott seeks U.S. and E.U. approvals for Humira as a treatment for juvenile rheumatoid arthritis

Abbott has announced it has simultaneously submitted a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMEA) seeking approval to market HUMIRA (adalimumab) as a treatment for juvenile rheumatoid arthritis (JRA) in the U.S. and juvenile idiopathic arthritis (JIA) in the European Union (EU).

9 May 2007

Phase III data on Safinamide in Parkinson's disease

Merck Serono S.A. has announced that Phase III data on safinamide, a new agent in Phase III development for the treatment of Parkinson's disease symptoms, were presented by Professor Fabrizio Stocchi at the American Academy of Neurology 59th Annual Meeting in Boston, Massachusetts, USA.

4 May 2007

$Treatment with zoledronic acid effective in reducing fractures in women with postmenopausal osteoporosis$

Treatment with zoledronic acid effective in reducing fractures in women with postmenopausal osteoporosis

A treatment for osteoporosis delivered once a year is as effective as current monthly or weekly osteoporosis regimens at reducing the incidence of bone fractures, according to a new study led by a UCSF research team.

4 May 2007

FDA wants new warnings on antidepressant medications

The U.S. Food and Drug Administration (FDA) has proposed that makers of all antidepressant medications update the existing black box warning on their products' labeling to include warnings about increased risks of suicidal thinking and behavior, known as suicidality, in young adults ages 18 to 24 during initial treatment (generally the first one to two months).

4 May 2007

Statins reduce risk of stroke and heart attack

People whose cholesterol improved after one month on cholesterol-lowering drugs called statins reduced their risk of stroke and heart attack, according to research that will be presented at the American Academy of Neurology's 59th Annual Meeting in Boston, April 28 , May 5, 2007.

4 May 2007

BioMarin starts phase 2a study of 6R-BH4 in sickle cell disease

BioMarin Pharmaceutical has announced that the first patient has initiated treatment in the Phase 2a clinical study of 6R-BH4 (sapropterin dihydrochloride) for the treatment of sickle cell disease (SCD).

4 May 2007

Reclast found to cause abnormal heart rhythms

An osteoporosis drug with the potential to cut the risk of spine fractures by 70 percent and the chance of hip fractures by 41 percent, has been found to have an adverse side effect on some women.

3 May 2007

Recommended doses of ginseng, ginko biloba do not interfere with drug absorption

Recent findings that the widely-used herbal supplement Saint John's wort could dramatically affect the absorption and metabolism of many prescription and non-prescription drugs raised concerns that other popular herbal supplements might cause similar changes, thus significantly altering drugs, therapeutic or toxic effects.

2 May 2007

Infliximab fails to improve chronic obstructive pulmonary disease symptoms

A promising anti-inflammatory drug failed to improve symptoms of moderate to severe chronic obstructive pulmonary disease, or COPD, in a large, multi-center trial.

2 May 2007

Adalimumab shows potential for Crohn's disease

A study led by Mayo Clinic found that adalimumab (HUMIRA) is an effective treatment for adults with Crohn's disease who do not respond to infliximab (REMICADE) therapy.

2 May 2007

Rituximab reduces disease activity in multiple sclerosis

A new drug under investigation shows a reduction in disease activity in multiple sclerosis (MS), according to two studies that will be presented at the American Academy of Neurology's 59th Annual Meeting in Boston. The drug reduced disease activity as indicated by MRI scans.

2 May 2007